January 28, 2016
January 28, 2016 - Terumo Corporation (Headquarters: Shibuya-ku, Tokyo, Japan; President and CEO: Yutaro Shintaku) and Quirem Medical B.V., a commercial stage Dutch medical technology company that focuses on radioembolization, today announced that Terumo will become the exclusive global distributor for the radioembolization solutions developed by Quirem Medical and has furthermore obtained a buy-out option.
Quirem Medical produces QuiremSpheres™, the next generation microspheres for the radioembolization treatment of liver tumors, which were originally developed by the University Medical Center (UMC) Utrecht, and received the European CE mark for quality and safety in April 2015. QuiremSpheres™, which contain the isotope holmium-166, have unique imaging capabilities by using both SPECT and MRI that may contribute to a more effective radioembolization treatment.
First product launch will take place in Europe during FY2016, and other territories will follow after completion of the required regulatory approvals and market access plans.
Peter Coenen, president of Terumo Interventional Systems EMEA and member of the Supervisory Board of Quirem Medical, commented: "QuiremSpheres™ have the potential to become a most valuable addition to our product range in the interventional oncology field. We regard the interventional oncology field as an exciting growth area for our company."
Jan Sigger, CEO of Quirem Medical, commented: "We are most pleased with this strategic alliance with Terumo as it will enable us to accelerate our global expansion, reflecting our ambition to make our solutions available to patients around the world and thereby build on the excellent reputation of Terumo in the market place."
Terumo is one of the world's leading medical device manufacturers in the interventional oncology field offering micro catheters, bland embolization beads, drug-eluting embolization beads, and many other related products. The addition of the QuiremSpheres™ microspheres, with their unique imaging capabilities, in its portfolio enables Terumo to offer new treatment options to physicians and patients and emphasizes Terumo's strong position in the interventional oncology field.
Radioembolization is a minimally invasive procedure that uses radiation therapy to treat liver cancer. Radioactive microspheres are injected into the blood vessels that feed the liver tumors, thereby delivering a high dose of radiation to the tumor while sparing normal tissue. It can help extend the lives of patients with inoperable tumors and improve their quality of life.
Tokyo-based Terumo Corporation is one of the world's leading medical device manufacturers with over $4 billion in sales and operations in more than 160 nations. Founded in 1921, the company develops, manufactures, and distributes world-class medical devices including products for use in interventional procedures, cardiovascular surgery, and transfusion medicine; the company also manufactures a broad array of syringe and hypodermic needle products for hospital and physician office use and also supplies drug delivery/injection devices to pharmaceutical firms. Terumo Corporation's shares are listed on the first section of the Tokyo Stock Exchange and are a component of the Nikkei, Japan's leading stock index.
Quirem Medical is an emerging medical device company with a mission to develop the next generation microspheres for targeted interventional oncology solutions.
(Notice) Among the information that Terumo discloses, the forward-looking statements including financial projections are based upon our assumptions using information available to us at the time and are not intended to be guarantees of future events or performance. Accordingly, it should be noted that actual results may differ from those forecasts on projections due to various factors. Factors affecting to actual results include, but are not limited to, changes in economic conditions surrounding Terumo, fluctuations of foreign exchange rates, and state of competition. The market share information in this press release is partly derived from our own independent research.